

1199SEIU Benefit and Pension Funds

SPECIALTY MEDICATIONS

available through Accredo Health Group, Inc., an Express Scripts specialty pharmacy

Call toll-free **(800) 803-2523**, 8:00 am to 8:00 pm, eastern time, Monday through Friday, to confirm that your medication is covered.

Effective as of January 1, 2017

- ◆ *Abraxane*® (paclitaxel protein-bound particles) [PA]
- Actemra*™ (tocilizumab) [PA] [QD] [ST]
- Actemra*™ SQ (tocilizumab) [PA] [QD] [PICA] [ST]
- ◆ *Actimmune*® (interferon gamma-1b) [PA][PICA]
- ◆ *Adcetris*® (brentuximab vedotin) [PA]
- Adcirca*® (tadalafil) [PA] [ST] [QD]
- Adempas*® (riociguat) [PA]
- Advate*® (antihemophilic factor [recombinant]) [CPA]
- Adynovate*™ (antihemophilic Factor VIII [recombinant]) [CPA]
- ◆ *Afinitor*® (everolimus) [PA] [QD] [PICA]
- Afstyla*® (antihemophilic Factor [recombinant]) [CPA]
- ◆ *Alcensa*® (alectinib) [PA] [PICA] [QD] [SF]
- Aldurazyme*® (laronidase) [CPA]
- Alphanate*® (antihemophilic factor [human]) [CPA]
- AlphaNine*® SD (coagulation factor IX [human]) [CPA]
- Alprolix*™ (coagulation factor IX [recombinant]) [CPA]
- Ampyra*™ (dalfampridine) [PA] [QD]
- Apokyn*® (apomorphine hydrochloride) [QD]
- Aralast*® NP (alpha[1]-proteinase inhibitor [human]) [PA]
- ◆ *Aranesp*® (darbepoetin alfa) [PA] [PICA]
- Arcalyst*® (rilonacept) [PA] [QD] [PICA]
- * *Arixtra*® (fondaparinux sodium) [PICA]
- ◆ *Arranon*® (nelarabine) [PA]
- ◆ *Arzerra*® (ofatumumab) [PA]
- Aubagio*® (teriflunomide) [PA] [ST]
- ◆ *Avastin*® (bevacizumab) [PA] [QD]
- Avonex*® (interferon beta-1a) [PA] [PICA]
- Azacitidine* (GENERIC) [PA] [QD]
- Bebulin*® VH (factor IX complex) [CPA]
- ◆ *Bendeka*™ (bendamustine) [PA]
- BeneFIX*® (coagulation factor IX [recombinant]) [CPA]
- Benlysta*® (belimumab) [PA]
- Berinerit*® (c1 esterase inhibitor [human]) [PA] [QD]
- Betaseron*® (interferon beta-1b) [PA] [PICA]
- Bethkis*® (tobramycin)
- Bexarotene* (GENERIC)
- Bivigam*™ (immune globulin intravenous [human]) [PA]
- ◆ *Bosulif*® (bosutinib) [PA] [SF] [QD]
- Botox*® (botulinum toxin type A) [PA] [PICA]
- ◆ *Capecitabine* (GENERIC) [PICA]
- Carbaglu*™ (carglumic acid)
- Carimune*® NF (immune globulin intravenous [human]) [PA]
- Cayston*® (aztreonam) [PA] [QD]
- Cerdelga*® (eliglustat tartrate)
- Cerezyme*® (imiglucerase) [CPA] [ST]
- Cimzia*® (certolizumab pegol) [ST] [PA] [QD] [PICA]
- Cinryze*® (c1 esterase inhibitor) [PA] [QD]
- ◆ *Cabometyx*™ (cobozantinib) [PA][QD] [SF]

◆ If the indication is CANCER, and the drug is subject to management by the eviCore Comprehensive Oncology Management Program, please call **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail-order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can call Accredo Customer Service at **(800) 467-2006** and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- Copaxone*® (glatiramer acetate) [PA] [PICA]
Copegus® (ribavirin) [PA] [SF]
Corifact® (factor XIII [human]) [CPA]
Cosentyx® (secukinumab) [PA] [PICA]
◆ *Cotellic*® (cobimetinib) [PA] [PICA] [QD]
CytoGam® (cytomegalovirus immune globulin intravenous [human]) [CPA]
Cytovene® IV (ganciclovir sodium)
Daklinza™ (daclatasvir) [PA] [QD] [SF]
◆ *Darzalex*® (daratumumab) [PA]
◆ *Decitabine* (GENERIC)
Duopa® (levodopa/carbidopa)
Dysport® (abobotulinumtoxinA) [PA]
Egrifta® (tesamorelin) [PICA]
Elaprase® (idursulfase) [CPA]
◆ *Eligard*® (leuprolide acetate) [PA][PICA]
Eloctate™ (antihemophilic factor [recombinant]) [CPA]
◆ *Empliciti*™ (elotuzumab) [PA]
Enbre® (etanercept) [PA] [QD] [PICA][ST]
* *Enoxaparin sodium* (GENERIC) [PICA]
Entyvio® (vedolizumab) [PA]
Epclusa® (sofosbuvir/velpatasvir) [PA][QD][SF]
◆ *Epogen*® (epoetin alfa) [PA] [PICA]
Epoprostenol sodium (GENERIC) [ST]
◆ *Erbix*® (cetuximab) [PA] [QD]
◆ *Erivedge*™ (vismodegib) [PA] [QD] [SF]
Esbriet® (pirfenidone) [PA]
Euflexxa® (sodium hyaluronate) [PA] [QD]
Exjade® (deferasirox) [SF]
Extavia® (interferon beta-1b) [ST] [PA] [PICA]
Eylea™ (afibercept) [PA]
Fabrazyme® (agalsidase beta) [CPA]
◆ *Farydak* (panobinostat) [PA] [PICA] [QD]
Feiba® VH (anti-inhibitor coagulant complex) [CPA]
Firazyr® (icatibant) [PA] [QD] [PICA]
◆ *Firmagon*® (degarelix) [PA] [PICA]
Flebogamma® (immune globulin [human]) [PA]
Flolan® (epoprostenol sodium) [PA]
◆ *Foloty*™ (pralatrexate) [PA]
* *Fondaparinux sodium* (GENERIC) [PICA]
Forteo® (teriparatide [rDNA origin]) [PA] [PICA]
* *Fragmin*® (dalteparin sodium) [PICA]
Fuzeon® (enfuvirtide) [PICA]
GamaSTAN® S/D (immune globulin [human])
Gammagard® Liquid (immune globulin [human]) [PA]
Gammagard® S/D (immune globulin [human]) [PA]
Gammaked™ (immune globulin, gamma caprylate [IGG]) [PA]
Gammaplex® (immune globulin [human]) [PA]
Gamunex® (immune globulin [human]) [PA]
Ganciclovir (GENERIC)
Gattex® (teduglutide)
◆ *Gazyva*™ (obinutuzumab) [PA]
Gel-One® (hyaluronate sodium) [PA]
Genotropin® (somatotropin [rDNA origin]) [PA] [PICA]
Gilenya™ (afatinib) [PA] [ST]
◆ *Gilotrif*™ (afatinib) [PA] [PICA] [QD]
Glassia™ (alpha [1]-proteinase inhibitor [human]) [PA] [ST]
Glatopa® (glatiramer acetate) [PA] [PICA]
◆ *Granix*™ (tbo-filgrastim) [PA] [PICA]
◆ *Halaven*™ (eribulin mesylate) [PA]
Harvoni™ (ledipasvir/sofosbuvir) [PA] [QD] [SF]
Helixate® FS (antihemophilic factor [recombinant]) [CPA]
Hemofil® M (antihemophilic factor [human]) [CPA]
◆ *Herceptin*® (trastuzumab) [PA]
Hetlioz™ (tasimelteon) [PA]
Hizentra™ (immune globulin subcutaneous [human]) [PA]

◆ If the indication is CANCER, and the drug is subject to management by the eviCore Comprehensive Oncology Management Program, please call **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail-order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can call Accredo Customer Service at **(800) 467-2006** and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- H.P. Acthar*® Gel (corticotropin) [PA] [QD]
- Humate-P*® (antihemophilic factor/von Willebrand factor complex [human]) [CPA]
- Humatrope*® (somatotropin [rDNA origin]) [PA] [PICA]
- Humira*® (adalimumab) [PA] [QD] [PICA]
- Hyalgan*® (sodium hyaluronate) [PA] [QD]
- ◆ *Hycamtin*® capsules (topotecan) [PA]
- Hymovis*® (hyaluronate sodium) [PA]
- HyperRho*® S/D (Rho[D] immune globulin [human])
- Hyqvia*™ (immune globulin infusion 10% [human] with recombinant) [PA]
- ◆ *Ibrance*® (palbociclib) [PA] [PICA] [QD]
- Idelvion*® (coagulation factor IX [recombinant]) [CPA]
- Ilaris*® (canakinumab) [PA] [QD]
- Iluvien*® (fluocinolone)
- ◆ *Imatinib* (GENERIC) [PA] [PICA] [QD]
- Increlex*® (mecasermin [rDNA origin]) [PA] [PICA]
- Infergen*® (interferon alfacon-1) [PICA]
- ◆ *Inlyta*® (axitinib) [PA] [QD] [PICA] [SF]
- ◆ *Intron*® A (interferon alfa-2b) [PA] [PICA]
- * *Iprivask*® (desirudin)
- ◆ *Iressa*® [PA] [PICA] [QD] [SF]
- ◆ *Istodax*® (romidepsin) [PA] [QD]
- ◆ *Ixempra*® (ixabepilone) [PA]
- Ixinity*® (coagulation factor IX [recombinant]) [CPA]
- Jadenu*™ (deferasirox) [SF]
- ◆ *Jakafi*™ (ruxolitinib) [PA] [SF] [QD]
- ◆ *Jevtana*® (cabazitaxel) [PA] [QD]
- ◆ *Kadcyla*™ (ado-trastuzumab emtansine) [PA]
- Kalbitor*® (ecallantide) [PA] [QD]
- Kalydeco*™ (ivacaftor) [PA] [SF]
- Kitabis Pak*® (tobramycin)
- Koate*®-DVI (antihemophilic factor [human]) [CPA]
- Kogenate*® FS (antihemophilic factor [recombinant]) [CPA]
- Kovaltry*® (antihemophilic factor VIII) [CPA]
- Krystexxa*™ (pegloticase) [PA]
- Kuvan*® (sapropterin dihydrochloride) [PA]
- Kynamro*™ (mipomersen sodium)
- ◆ *Lartruvo*™ (olaratumab) [PA]
- Lemtrada*™ (alemtuzumab) [PA]
- ◆ *Lenvima*™ (lenvatinib) [PA] [PICA] [SF]
- Letairis*® (ambrisentan) [PA] [QD]
- ◆ *Leukine*® (sargramostim) [PA] [PICA]
- Leuprolide acetate* (GENERIC) [PICA]
- Liletta*™ (levonorgestrel-releasing intrauterine device)
- ◆ *Lonsurf*® (tipiracil/trifluridine) [PA] [PICA]
- * *Lovenox*® (enoxaparin sodium) [PICA]
- Lucentis*® (ranibizumab) [PA]
- Lumizyme*™ (alglucosidase alfa) [CPA]
- Lupaneta*™ (leuprolide acetate) [PICA]
- Lupron Depot*® (leuprolide acetate) [PA] [PICA]
- Lupron Depot-PED*® (leuprolide acetate) [PA] [PICA]
- ◆ *Lynparza*™ (olaparib) [PA] [SF] [PICA]
- Macugen*® (pegaptanib sodium injection) [PA]
- Makena*™ (hydroxyprogesterone caproate) [PA]
- ◆ *Mekinist*™ (trametinib) [PA] [PICA] [QD]
- MICRhoGAM*® (Rho[D] immune globulin [human])
- Mitoxantrone HCl* (GENERIC)
- Moderiba*™ (ribavirin) [PA]
- Monoclate-P*® (antihemophilic factor [human]) [CPA]
- Mononine*® (coagulation factor IX [human]) [CPA]
- ◆ *Mozobil*® (plerixafor) [QD] [PA] [PICA]
- Myalept*™ (metreleptin) [PA] [PICA]
- Myobloc*® (botulinum toxin type B) [PA] [PICA]
- Naglazyme*® (galsulfase) [CPA]
- Natpara*® (parathyroid hormone) [PA] [PICA]
- ◆ *Neulasta*® (pegfilgrastim) [PA] [PICA]

◆ If the indication is CANCER, and the drug is subject to management by the eviCore Comprehensive Oncology Management Program, please call **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail-order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can call Accredo Customer Service at **(800) 467-2006** and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- Neumega*® (oprelvekin) [PICA]
- ◆ *Neupogen*® (filgrastim) [PA] [PICA]
 - ◆ *Nexavar*® (sorafenib) [PA] [QD] [PICA] [SF]
 - ◆ *Ninlaro*® (ixazomib) [PA] [PICA] [QD]
 - Norditropin*® (somatropin [rDNA origin]) [PA] [PICA]
 - Norditropin/Nordiflex*® (somatropin [rDNA origin]) [PA] [PICA]
 - Northera*® (droxidopa) [PA]
 - NovoEight*® (antihemophilic factor VIII [recombinant]) [CPA]
 - NovoSeven*® RT (coagulation factor VIIa [recombinant]) [CPA]
 - Nplate*® (romiplostim) [PA]
 - Nucala*™ (mepolizumab) [PA]
 - Nulojix*® (belatacept)
 - Nuplazid*™ (pimavanserin) [SF]
 - Nutropin*® (somatropin [rDNA origin]) [PA] [PICA]
 - Nutropin AQ*® (somatropin [rDNA origin]) [PA] [PICA]
 - Nuwig*® (antihemophilic Factor VIII [recombinant]) [CPA]
 - Ocaliva*™ (obeticholic acid) [PA][QD]
 - Octagam*® (immune globulin intravenous [human]) [PA]
 - Octreotide acetate* (GENERIC)
 - ◆ *Odomzo*® (sonidegib) [PA][PICA]
 - Ofev*® (Nintedanib) [PA]
 - Olysio*™ (simeprevir) [PA] [SF]
 - Omnitrope*® (somatropin) [PA] [PICA]
 - ◆ *Opdivo*® (Nivolumab) [PA]
 - Opsumit*® (macitentan) [PA]
 - Orencia*® IV (abatacept intravenous) [PA] [PICA]
 - Orencia*® SC (abatacept subcutaneous) [ST] [PA] [QD] [PICA]
 - Orenitram*™ (treprostinil) [PA]
 - Orkambi*® (lumacaftor/ivacaftor) [PA]
 - OrthoVisc*® (hyaluronate sodium) [PA]
 - Otezla*® (apremilast) [PA] [ST]
 - Ozurdex*™ (dexamethasone)
 - ◆ *Pegasys*® (peginterferon alfa-2a) [PA] [PICA] [SF]
 - ◆ *Perjeta*™ (pertuzumab) [PA]
 - Plegridy*™ (peginterferon Beta-1A) [PA] [PICA]
 - ◆ *Pomalyst*® (pomalidomide) [PA] [PICA]
 - Praluent*® (alirocumab) [PA]
 - Privigen*® (immune globulin intravenous [human]) [PA]
 - ◆ *Procrit*® (epoetin alfa) [PA] [PICA]
 - Procysbi*™ (cysteamine bitartrate)
 - Profilnine*® SD (factor IX complex [human]) [CPA]
 - ◆ *Proleukin*® (aldesleukin) [PA]
 - Prolia*™ (denosumab) [PA] [QD]
 - Promacta*® (eltrombopag) [PA] [QD]
 - ProThelia*™ (sucralfate)
 - Pulmozyme*® (dornase alfa)
 - Ravicti*™ (glycerol phenylbuterate)
 - Rebetol*® (ribavirin) [PA]
 - Rebif*® (interferon beta-1a) [PA] [PICA]
 - Recombine*™ (antihemophilic factor [recombinant]) [CPA]
 - Remicade*® (infliximab) [PA]
 - Remodulin*® (treprostinil sodium) [ST]
 - Repatha*™ (evolocumab) [PA]
 - Retisert*® (fluocinolone acetonide) [QD]
 - Revatio*® injection (sildenafil citrate) [PA] [QD]
 - Revatio*® tablets (sildenafil citrate) [PA] [QD]
 - ◆ *Revlimid*® (lenalidomide) [PA] [QD] [PICA]
 - RhoGAM*® (RHo[D] immune globulin [human])
 - Rhophylac*® (RHo[D] immune globulin intravenous [human])
 - RiaSTAP*® (fibrinogen)
 - RibaPak*® (GENERIC) [PA]
 - Ribasphere*® (GENERIC) [PA] [SF]
 - Ribavirin* (GENERIC) [PA] [SF]
 - ◆ *Rituxan*® (rituximab) [PA]
 - Rixubis*™ (coagulation factor IX [recombinant]) [CPA]
 - Rucones*™ (c1 Esterase Inhibitor [recombinant]) [PA]

◆ If the indication is CANCER, and the drug is subject to management by the eviCore Comprehensive Oncology Management Program, please call **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail-order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can call Accredo Customer Service at **(800) 467-2006** and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- Sabri*® (vigabatrin)
- Saizen*® (somatropin [rDNA origin]) [PA] [PICA]
- Samsca*® (tolvaptan) [QD]
- Sandostatin*® (octreotide acetate) [PICA]
- Sandostatin LAR*® (octreotide/IM) [PICA]
- Sensipar*® (cinacalcet hydrochloride) [PA] [QD]
- Serostim*® (somatropin [rDNA origin]) [PA] [PICA]
- Signifor*® (pasireotide dispartate) [PA]
- Signifor*® LAR (pasireotide pamoate) [PA] [PICA]
- Sildenafil* (GENERIC) [ST] [QD]
- Simponi*™ (golimumab) [ST] [PA] [QD] [PICA]
- Simponi*™ ARIA™ (golimumab) [ST] [PA] [QD] [PICA]
- Soliris*® (eculizumab)
- Somatuline Depot*® (lanreotide) [PICA]
- Somavert*® (pegvisomant)
- Sovaldi*™ (sofosbuvir) [PA] [QD] [SF]
- Spinraza*™ (nusinersen)
- ◆ *Sprycel*® (dasatinib) [PA] [QD] [PICA] [SF]
- Stelara*™ (ustekinumab) [PA] [QD] [PICA]
- Stimate*® (desmopressin acetate)
- ◆ *Stivarga*® (regorafenib) [PA] [QD]
- Supartz*® (sodium hyaluronate) [PA] [QD]
- Supprelin*® LA (histrelin acetate)
- ◆ *Sutent*® capsules (sunitinib malate) [PICA] [QD]
- Sylatron*™ (peginterferon alfa-2b)
- Sylvant*™ (siltuximab)
- Synagis*® (palivizumab) [PA] [QD]
- Synvisc*®/Synvisc-ONE® (hylan G-F 20) [PA] [QD]
- ◆ *Tafinlar*® (dabrafenib) [PA] [PICA] [QD] [SF]
- ◆ *Tagrisso*™ (osimertinib) [PA] [PICA] [QD]
- Taltz*® (ixekizumab) [PA] [QD] [PICA] [ST]
- ◆ *Tarceva*® (erlotinib) [PA] [QD] [PICA] [SF]
- ◆ *Tasigna*® (nilotinib) [PA] [QD] [PICA] [SF]
- ◆ *Tecentriq*™ (atezolizumab) [PA]
- Tecfidera*™ (dimethyl fumarate) [PA] [ST]
- Technivie*™ (ombitasvir/paritaprevir/ritonavir) [PA] [SF]
- ◆ *Temodar*® (temozolomide) [PA] [PICA]
- Temozolomide* (GENERIC) [PICA]
- Tetrabenazine* (GENERIC)
- ◆ *Thalomid*® (thalidomide) [PA] [PICA]
- Tobi*® (tobramycin)
- Tobi-Podhaler*® (tobramycin)
- Tobramycin* (GENERIC)
- ◆ *Torisel*® (temsirolimus) [PA]
- Tracleer*® (bosentan) [PA] [QD]
- ◆ *Treanda*® (bendamustine) [PA]
- Tretten*® (coagulation factor XIII A-subunit [recombinant]) [CPA]
- ◆ *Tykerb*® (lapatinib) [PA] [QD] [PICA]
- Tysabri*® (natalizumab) [PA] [QD]
- Tyvaso*® (treprostinil) [PA]
- Uptravi*® (selexipag)
- ◆ *Valchlor*™ (mechlorethamine) [PA]
- ◆ *Vantas*® (histrelin) [PA]
- ◆ *Vectibix*® (panitumumab) [PA]
- ◆ *Velcade*® (bortezomib) [PA]
- Veletri*® (epoprostenol sodium)
- Veltassa*™ (paitromer)
- Ventavis*® (iloprost) [PA] [QD]
- ◆ *Vidaza*® (azacitidine) [PA] [QD] [PICA]
- Viekira Pak* (ombitasvir/paritaprevir/ritonavir co-packed with dasabuvir) [PA] [QD] [SF]
- Vimizim*™ (elosulfase alfa) [CPA]
- Visudyne*® (verteporfin)
- Vivitrol*® (naltrexone)
- ◆ *Votrient*® (pazopanib) [PA] [QD] [PICA] [SF]
- Vpriv*™ (velaglucerase alfa) [CPA]

◆ If the indication is CANCER, and the drug is subject to management by the eviCore Comprehensive Oncology Management Program, please call **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail-order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can call Accredo Customer Service at **(800) 467-2006** and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- Wilate*® (von Willebrand factor/coagulation factor VIII complex [human]) [CPA]
- WinRho SDF*® (Rho[D] immune globulin intravenous [human])
- ◆ *Xalkori*® (crizotinib) [PA] [QD] [PICA] [SF]
- Xeljanz*® (tofacitinib citrate) [PA]
- Xeljanz XR*® (tofacitinib) [PA]
- Xenazine*® (tetrabenazine) [PA] [QD] [SF]
- Xeomin*® (incobotulinumtoxinA) [PA]
- ◆ *Xgeva*™ (denosumab) [QD]
- Xiaflex*™ (collagenase clostridium histolyticum)
- Xolair*® (omalizumab) [PA] [QD]
- ◆ *Xtandi*® (enzalutamide) [PA] [QD] [SF]
- Xyntha*® (antihemophilic factor [recombinant]) [CPA]
- ◆ *Yervoy*™ (ipilimumab) [PA] [QD]
- ◆ *Zaltrap*® (afibercept) [PA]
- ◆ *Zarxio* (GENERIC) [PA] [PICA]
- Zavesca*® (miglustat) [QD][CPA]
- ◆ *Zelboraf*™ (vemurafenib) [PA] [QD] [PICA] [SF]
- Zemaira*® (alpha [1]-proteinase inhibitor [human]) [PA]
- Zepatier*™ (elbasvir/grazoprevir) [PA] [QD] [SF]
- ◆ *Zoladex*® (goserelin acetate) [PA] [PICA]
- ◆ *Zolinza*® (vorinostat) [PA] [QD] [PICA] [SF]
- Zomactor*® (somatropin [rDNA origin]) [PA] [PICA]
- Zorbtive*® (somatropin [rDNA origin]) [PA] [PICA]
- ◆ *Zykadia*™ (ceritinib) [PA] [PICA] [QD] [SF]
- ◆ *Zytiga*™ (abiraterone acetate) [PA] [QD] [PICA] [SF]

◆ If the indication is CANCER, and the drug is subject to management by the eviCore Comprehensive Oncology Management Program, please call **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail-order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can call Accredo Customer Service at **(800) 467-2006** and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.